WO2002033117A2 - Procede d'analyses genomique/proteomique en tandem de cellules de proliferation - Google Patents

Procede d'analyses genomique/proteomique en tandem de cellules de proliferation Download PDF

Info

Publication number
WO2002033117A2
WO2002033117A2 PCT/US2001/032540 US0132540W WO0233117A2 WO 2002033117 A2 WO2002033117 A2 WO 2002033117A2 US 0132540 W US0132540 W US 0132540W WO 0233117 A2 WO0233117 A2 WO 0233117A2
Authority
WO
WIPO (PCT)
Prior art keywords
cells
data
nucleic acid
proliferating cells
monolayer
Prior art date
Application number
PCT/US2001/032540
Other languages
English (en)
Other versions
WO2002033117A3 (fr
Inventor
Paul L. Kornblith
Maryann Donovan-Peluso
Original Assignee
Precision Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Precision Therapeutics, Inc. filed Critical Precision Therapeutics, Inc.
Priority to AU2002224435A priority Critical patent/AU2002224435A1/en
Priority to US10/399,563 priority patent/US20040086888A1/en
Publication of WO2002033117A2 publication Critical patent/WO2002033117A2/fr
Publication of WO2002033117A3 publication Critical patent/WO2002033117A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B50/00—ICT programming tools or database systems specially adapted for bioinformatics

Definitions

  • a proliferative disease i.e., a disease or condition, such as cancer or psoriasis, in which cells proliferate in an abnormal fashion
  • a proliferative disease i.e., a disease or condition, such as cancer or psoriasis, in which cells proliferate in an abnormal fashion
  • an aberrant or aberrantly expressed gene or gene product is identified and, through a variety of well-known methodologies, the sequence of the gene may be determined and the expression of the gene may be evaluated. Through laborious experimentation and exploration, the relationship between expression of a gene and treatments/outcomes may be determined.
  • nucleic acids in a biopsy of a proliferating tissue.
  • the expression levels of a particular gene and/or the presence of polymo ⁇ hisms may be determined.
  • the methods for evaluating the nucleic acids of the proliferating tissue are many and include, without limitation, hybridization studies (i.e., Southern and Northern blots); nucleic acid sequencing; finge ⁇ rinting (i.e., the analysis of restriction fragment length polymo ⁇ hisms); and PCR-based protocols, which may be quantitative and/or qualitative in nature.
  • These protocols may be performed in a traditional manner, i.e., by running the results on a gel, or by newer methods. These newer methods involve miniaturization and multiplication of the traditional protocols and include nucleic acid microarrays and a variety of applications that may be performed in connection with such microarrays (i.e., without limitation, DNA:DNA or DNA:RNA hybridizations and/or competitive hybridizations).
  • the arrays permit the rapid analysis of a nucleiG acid sample for the presence or absence of 12,000 or more independent nucleic acids. These independent nucleic acids may be of known genes or of unknown genes [i.e., expressed sequence tags (ESTs)].
  • RNA (expression) levels One particular difficulty in using the above-described assays to identify the altered expression of or sequence of a given gene or other target DNA in proliferating cells in a tumor is that in most cases the proliferating cell is mixed in with other normal cells, such as fibroblasts. Typically, the actual proliferating cell comprises less than 5% of the cell population in a given biopsy. In assays that analyze sequence differences between normal and proliferating cells, if the differences between the two DNAs are large enough, the normal and proliferative nucleic acids may be distinguished. However, more subtle differences may not be distinguishable from the background of normal nucleic acids. This problem is compounded in assays that quantify RNA (expression) levels.
  • RNAs Only the most macroscopic of deviations in quantities of RNA are detectable when the deviant RNAs form only a small percentage (i.e., 0.1-5%) of a mixed pool (population) of RNAs. "Subtler" deviations in RNA levels will remain undetectable. In this case, a "subtler" deviation may actually be a gross deviation, such as a 1000% increase in the expression of a particular gene. For example, a mixed pool of RNA, a 1000% increase in the quantity of a given RNA species 2% of the cells in a biopsy will appear as a 20% increase in the presence of a given RNA. Similarly, a 100% increase in transcription of a given gene would result in only a 4% increase in overall RNA levels in the mixed population. These deviations (4-20%) may be undetectable, or at least statistically insignificant, in many assay systems. This difficulty prevents the realization of the power of certain combinatorial and/or miniaturized assays, such as microarray technologies.
  • substantially pure populations of proliferating cells from "background,” i.e., normal, cells in order to provide nucleic acid populations that are suitable for conducting statistically significant genetic analysis of the cells.
  • background i.e., normal
  • the isolation of substantially pure populations of such cells would not only provide a powerful means for identifying genetic markers specific to any given proliferative disease, but when applied to individual patients would be a powerful diagnostic and outcome-predicting (prognostic) tool. This would permit the realization of the power of combinatorial and/or miniaturized genetic assays, such as microarray technologies, and the computerized analysis thereof.
  • Non-genetic analysis i.e.
  • the resultant non-genetic data can be combined with the above- described genetic data to provide a complete and accurate profile of the proliferative cells of the tissue sample.
  • the present invention is directed to a novel process for producing data characterizing the nucleic acids in proliferating cells using a tandem protocol for simultaneously building and expanding genomics/proteomics cancer databases while coordinating present and future genomic/proteomic individual patient assays.
  • the protocol is comprised of culturing proliferating cells by collecting a tissue sample including the proliferating cells; mechanically dividing the sample into cohesive multicellular particulates; and growing a tissue culture monolayer from the multicellular particulates. Such monolayers can be frozen for future analytic and/or prognostic and diagnostic investigations.
  • the genetic data thus generated is then gathered to form a data set in a data structure that also includes data identifying the source of the tissue sample.
  • Clinical data specific to the patient from whom the tissue sample was taken may also be included in the data set.
  • RNA or DNA nucleic acid that is present in the proliferating cells
  • Analyses typically involve use of one or more analytical methods known to molecular biologists to characterize the nucleic acids, including, without limitation, quantitative methods that identify the amount of specific RNAs in a cell, and qualitative methods that determine the presence or absence of specific genetic markers, such as DNA or RNA sequence insertions, deletions or substitutions.
  • One important embodiment of the present invention involves the use of genomic and proteomic dynamic assays to analyze tumor cells grown in culture.
  • the method may further include the step of characterizing the proliferating cells by analyzing the genetic data in connection with a set of corresponding clinical data for statistically significant commonalities and/or trends.
  • the genetic/clinical correlative data can be used to generate one or more profiles which link one or more proliferative cell disease states with phenotypic and/or genotypic characterizations, diagnoses and/or prognoses.
  • the data and/or profiles may be encoded in a computer storage medium.
  • a method for diagnosing proliferative diseases is also provided that compares either 1) the genetic and corresponding clinical data and/or 2) the profiles generated therefrom, to data generated in connection with a new tissue sample.
  • a computer system containing the data and/or profiles is also provided that, optionally, allows dissemination and/or analysis of the data over a computer network.
  • Figs. 1A-1C are graphs of the growth rates of three independent cell cultures
  • Figs. 2A-2F through Figs. 5A-5F are graphs depicting the results of short- term and long-term chemotherapy assays as follows:
  • Figs. 2A-2F and Figs. 3A-3F show short-term and long-term assays for a first patient;
  • Figs. 4A-4F and Figs. 5A-5F show short-term and long-term assays for a second patient;
  • Figs. 6 and 7 show two radiation dose versus surviving fraction curves for two glioblastoma cell lines. Cells were irradiated in microtiter plates and assayed four days post-irradiation; Figs. 8A-8C are graphs of survival rates of cell cultures treated with radiation (Fig. 8A) or with radiation and Taxol (Figs. 8B and 8C);
  • Figs. 9A and 9B are graphs showing data from a series of experiments where target cells from two tumor types were exposed to Activated Natural Killer (ANK) cells; and Fig. 10 is a schematic diagram of a computer network for sharing the data generated by the methods of the present invention.
  • ANK Activated Natural Killer
  • the present invention is a novel process for producing data characterizing the nucleic acids in proliferating cells using a tandem protocol for simultaneously building and expanding genomics/proteomics cancer databases while coordinating present and future genomic/proteomic individual patient assays, with a two-way feedback system that enhances each.
  • This tandem genomic/proteomic concept consists of two initiatives that proceed side-by-side both at a first point in time and again at a later point in time with respect to samples of malignant tissue from a specific patient or patients.
  • the process includes the steps of selectively expanding a population of proliferating cells from a tissue sample, typically from a solid tumor, and subsequently extracting nucleic acid from cells of the expanded population. Characterization of the nucleic acid is performed according to the plethora of analytical techniques available to molecular biologists for quantitatively and/or qualitatively analyzing the nucleic acids.
  • the tandem genomic/proteomic protocol consists of taking the malignant cells of interest at point "A" in time to create a gene relationship database in which the generation of genetic data can be used to determine which gene or gene product relates to the response of a given agent.
  • Microarray assays are then performed to generate genetic data that is correlated to clinical cell lines in order to develop the database.
  • Gene assays are then performed in which antisense is produced for each gene or gene product associated with a given response. Production of antisense is then used as a reagent in a micro version of the cell-based assay system on cells that have been preselected as being representative of the original tumor, based on the fluorescent staining for the cell types and subtypes.
  • Such micro version assays can be used for patient diagnostic and prognostic pu ⁇ oses. Because the cells grown in the monolayer can be frozen for later use, the same genomic/proteomic database creation may be expanded at a later point "B" in time. Also, at point "B", a micro version genomic/proteomic assay of the patient cells for patient diagnostic and prognostic pu ⁇ oses may be conducted again. The comparison of the database and the patient assay may be conducted at point "A" in time, may be conducted at point "B” in time, and a further timeline comparison may be completed when all the data for points "A" and "B” are available.
  • the present invention also allows for a cellular-based live cell dead cell real time assay system using an ATP bioluminescence assay to determine tumor cell apoptosis levels based on ATP-ADP ratios.
  • the genomic/proteomic tandem protocol generates data by the analytical process of the present invention (hereinafter the "genetic data") that is then gathered to form a data set in a data structure that also includes data identifying the source of the tissue sample (the “sample source identifier," which is herein included in the meaning of the phrase “genetic data”).
  • Clinical data specific to the patient from whom the tissue sample was taken also may be included in the data set. The nature of the clinical data may vary, but it is preferred that the clinical data is more, rather than less, complete.
  • Clinical data may include, without limitation, general patient information, such as age, sex, height, weight, medical history, geographic area(s) of residence, travel habits, sexual activity and ethnicity.
  • Clinical data may also include, without limitation, data specific to the current medical state of the patient, such as symptoms; current and past medications; the quantity administered to the patient and the duration of treatment; other non-pharmaceutical treatments, such as surgery or radiation therapy; data indicating the size and number of tumors and their location in the patient; and other clinical data that indicate the general state of health and/or progression of the proliferative disease state in that patient, such as the outcome of treatments.
  • the clinical data also can include data generated in the analysis of cells expanded according to the methods of the present invention for sensitivity to drugs.
  • Data indicating the phenotype of the proliferating cells also may be included.
  • This phenotypic data includes, without limitation, histochemical, immunohistochemical, biochemical and growth characteristics of the cells and/or tumor, including the production of secreted compounds, whether or not the proliferative cells were cultured according to the methods of the present invention.
  • Phenotypic data that can be used to identify a particular proliferative disease state is referred to herein and in the appended claims as "phenotypic polymo ⁇ hisms characteristic of a proliferative disease state.”
  • the growth and analysis of a substantially pure population of proliferating cells of the present invention for drug or radiotherapy sensitivity and for both cellular and secreted phenotypic markers is described herein and in co-pending U.S. Patent Application Serial No. 09/189,310, filed November 10, 1998, which is inco ⁇ orated by reference, providing a comprehensive and unified system for monitoring a malignancy in a patient through the duration of the malignancy.
  • the cell culture method of the present invention permits the expansion of a population of proliferating cells in a mixed population of abnormal proliferating, cells and other (normal) cells.
  • the mixed population of cells typically is a biopsy or sample from a solid tumor.
  • a tissue sample from the patient is harvested, cultured and analyzed for genetic markers.
  • Subcultures of the cells produced by the culture methods of the present invention may be separately exposed to a plurality of treatments and/or therapeutic agents for the pu ⁇ ose of objectively identifying the best treatment for the cultured cells obtained from the patient.
  • the culture techniques of the present invention also result in a monolayer of cells that express cellular markers, secreted factors and tumor antigens in a manner representative of their expression in vivo.
  • tissue sample preparation techniques render this method practically, as well as theoretically, useful.
  • One particularly important tissue sample preparation technique is the initial preparation of cohesive multicellular particulates of the tissue sample, rather than enzymatically dissociated cell suspensions or preparations, for initial tissue culture monolayer preparation.
  • abnormal proliferating cells for example, malignant cells
  • Practical monolayers of cells may thus be formed to enable meaningful analysis of the nucleic acids of the cells, screening of a plurality of treatments and/or agents, the identification of cellular markers, and for use in a wide variety of applications, including pathology and vaccine preparation.
  • Proteomic dynamic assays may include, without limitation, functional assays to quantitate protein activity (e.g., presence or absence of urokinase or MMP2); and tumor cell protein expression using medium-based assays for angiogenesis factors, tumor markers, and growth factors or soluble growth factor receptors.
  • functional assays to quantitate protein activity e.g., presence or absence of urokinase or MMP2
  • tumor cell protein expression e.g., tumor cell protein expression using medium-based assays for angiogenesis factors, tumor markers, and growth factors or soluble growth factor receptors.
  • Genomic dynamic assays may include, without limitation, gene expression profiling and pharmacogenomic analysis of individual tumor expression profiles using microarray analysis or expression PCR; gene mutation analysis using PCR-sequence analysis; gene therapy that includes he ⁇ es-TK ganciclovir suicide gene, p53 transduction effect on chemoresponse and antisense therapy; and gene expression profiling in pre- and post-treatment cells so as to correlate tumor chemoresponse with genotype.
  • Cell phenotype functional dynamic assays may include, without limitation, tumor cell phenotype assays, such as adhesion, migration, chemotaxis and invasion analysis and functional assays to evaluate new cytostatic therapeutics for chronic disease management, such as herceptin effects on HER2/neu protein levels in breast cancer, anti-adhesion peptides, anti-angiogenesis peptides and antibodies, and anti- protease anti-invasion peptides and antibodies.
  • combination proteomic/genomic dynamic assays may include, without limitation, single cell analysis, such as characterization of individual cells, as well as tumor populations and high-throughput multiparameter screens.
  • Drug assays can be used to monitor the growth of cells in order to ascertain the time to initiate the assay and to determine the growth rate of the cultured cells; sequence and timing of drug addition is also monitored and optimized. By subjecting uniform samples of cells to a wide variety of active agents (and concentrations thereof), the most efficacious agent can be determined. For assays concerning cancer treatment, a two-stage evaluation is contemplated in which both acute cytotoxic and longer-term inhibitory effects of a given anti-cancer agent are investigated.
  • the initial culturing of multicellular particulates it is believed (without any intention of being bound by the theory) that because the abnormal proliferating cells are grown, under such conditions, closer to that which is found in vivo, the cells express cellular markers, secreted factors and tumor antigens in a manner more closely resembling their expression in vivo.
  • the culture media obtained from growing a monolayer according to the inventive method or by histochemically and/or immunohistochemically assaying the cells grown, under such conditions, a more accurate profile of the cellular markers or factors is obtained.
  • the data may be analyzed without the aid of a computer.
  • a certain genetic defect is present in the diseased proliferating cells.
  • the over-expression of one or more genes that is characteristic of a certain disease state may be readily visualized.
  • the strength of the process of the present invention lies in the use of computers to analyze the genetic data in connection with the clinical data and as an aid in diagnosis or prognosis. Therefore, the genetic and clinical data typically are stored in a computer data structure (database) for analysis and/or extraction at a later date.
  • the above-described data structure is encoded in a computer storage medium in a form that allows searching of the data, input of additional data and/or data mining.
  • the data structure forms a part of a database that is searchable by use of one or more of the large number of database search engines that are broadly available.
  • the searches may be structured to limit the access of users of the database to specific types of searches, or unstructured, so that end users may define searches that are limited only by the types of searches available in the search engine being used.
  • the data also may be made available in a form that permits data mining.
  • Data mining Knowledge Discovery in Databases or KDD
  • KDD Knowledge Discovery in Databases
  • the above-described process for establishing relations between the genetic data and the clinical data is a form of data mining since new relationships are discovered by this process. It uses machine learning, statistical and visualization techniques to discover and present knowledge in a form that is easily comprehensible to humans.
  • Data mining typically is expedited by the use of computers and may be performed by the use of one or more of the large variety of commercially available software programs that enable computerized data mining. Standard database search engines may be used for data mining, but programs are available that are much more efficient and capable.
  • Access to the data and/or database encoded on the computer storage medium may be on a single-user personal computer (PC) or workstation.
  • the data and/or database also may be accessed over a computer network of two or more PCs or workstations.
  • computer network it is meant any connection between two computing devices by which data can be shared or transferred.
  • Computer networks include, without limitation, remote direct connections, by modem or otherwise; local area networks (LANs); intranets; extranets (wide area networks, or WANs); the Internet (including the World Wide Web) or other worldwide computer networks.
  • LANs local area networks
  • intranets intranets
  • extranets wide area networks, or WANs
  • the Internet including the World Wide Web
  • Also included in the definition of "computer network” are computer file sharing communities that allow location of and sharing of data files over large computer networks, such as the Internet.
  • Examples of such communities are, without limitation, the Napster (client/server), Gnutella and FreeNet (peer-to-peer) paradigms.
  • the term "computer” is to be given its broadest inte ⁇ retation, including without limitation, PCs, workstations, mainframes, servers and computing appliances.
  • computer storage medium includes any device, internal or external, permanent or removable, in which data can be stored, either temporarily or permanently, for use in connection with a computer.
  • Permanent storage media includes magnetic-, optical- or hardware-based media. Examples of magnetic media include, without limitation, hard drives, floppy drives, magnetic tapes and other removable magnetic media, i.e., zip drives.
  • Optical media include, without limitation, CD-ROM, CD-R, CD-RW, DVD-ROM and DVD-RAM media.
  • Hardware-based media include conventional RAM (i.e., temporary storage of the data in a computer's volatile RAM), ROM and other firmware that can store the data, either temporarily or permanently, and is permanently or removably stored in connection with a computing device.
  • raw genetic and clinical data is encoded in a computer storage medium in a form that permits mining of the data or otherwise permits inte ⁇ retation of the data.
  • a statistically significant number of records sets of data corresponding the genetic and clinical data for a single tissue sample
  • generalities may be made about the data and profile(s) may be generated and stored in searchable form. For instance, there may be enhanced expression of a particular gene (i.e., EGFR) in tumors of a certain origin and having certain phenotypic characteristics (i.e., the presence of thrombogenic factors).
  • the creation of statistically significant profiles enables production of a database which can be searched by physicians and clinical laboratory personnel to aid in diagnoses and prognoses.
  • the data may be updated anytime new specimens are analyzed.
  • the data may be entered remotely by end users or at a central location by a person or organization that maintains the database. Entry of the new data can be accomplished by a variety of software interfaces, typically customized database software, that permits entry of new records into a database. These interfaces are so common and variable in structure that they are not described herein in further detail.
  • an end user may manually enter clinical data into the database, while the raw data from a microarray reader is entered automatically into the database to lessen the likelihood of data manipulation or errors in the communication of the data to the database.
  • the broad availability of the database including microarray data derived from cells cultured according to the methods of the present invention will permit rapid compilation of statistically significant and meaningful data for a large number of proliferative disease states.
  • the analyzing step may be either partially or fully automated by robotic devices.
  • the network includes a plurality of workstations 10 in data communication with a process 20 which is in data communication with data sets 30, 31 and 32.
  • the data sets 30, 31 and 32 include a data set 30 containing genetic data; a data set 31 containing clinical data corresponding to the genetic data; and a data set 32 containing profiles derived from the data mining of data sets 30 and 31.
  • Data communication pathways 40 connect the data sets 30, 31 and 32 with the process 20 and the workstations 10.
  • Process 20 and/or data sets 30, 31 and 32 are optionally contained within any one or distributed between all of workstations 10, and/or in a separate device, such as a server and/or in data storage devices attached to or housed within the workstations 10 and/or server.
  • Workstations 10 can be any computing device having a display and a data input means, such as a keyboard and mouse.
  • Process 20 is performed by a computer and includes data search, data input and analysis functions. The functions are performed by software and/or hardware structures in the computer. Data in data sets 30 and 31 are analyzed by a data mining function of process 20 to generate profiles that link genetic and clinical data which are stored in data set 32.
  • Data communication pathways 40 are any pathway by which data can be transferred, including electrical, electromagnetic and optical pathways.
  • Central to the present invention is the method for selecting a population of proliferating cells from a tissue sample or biopsy.
  • the method of the present invention also allows for initial identification, tracking, and analyzing of an individual patient's malignancy; identification of malignancy-specific cellular or secreted markers and of cellular or secreted markers indicative of complications; study of the invasiveness and aggressiveness of the malignancy; study of the growth rate of the malignancy; study of the effect of therapies on the malignancy as compared to control cells of the same patient (chemosensitivity and/or radiosensitivity versus theratoxicity) and the identification of a therapeutic index (i.e., the ratio of chemosensitivity.theratoxicity); study of tumor mo ⁇ hology; and study of histological, cytochemical and immunocytochemical markers.
  • the method of the present invention also permits accurate genetic analysis of malignant cells as well as the gathering, analysis, and dissemination of data specific to a given patient.
  • the method of the present invention includes the steps of collecting a tissue sample or specimen of a patient's cells and separating the specimen into cohesive multicellular particulates (explants) of the tissue sample, rather than enzymatically digested cell suspensions or preparations.
  • the cells are then grown as a tissue culture monolayer from the multicellular particulates to form a prime culture.
  • a specimen can be taken from a patient at any relevant site including, but not limited to, tissue, ascites or effusion fluid. Samples may also be taken from body fluid or exudates as is appropriate.
  • a tissue culture monolayer can be grown in any method known in the art for growing such a monolayer, for instance, in tissue culture plates or flasks.
  • prime culture Once a prime culture is established from a patient's abnormal proliferating cells, the prime culture can be maintained without any treatment besides normal feedings and passage techniques as indicative of the growth of the cells absent treatment with a therapeutic regimen. Subcultures of the prime culture are prepared so that the cells of the prime culture are not affected by any subsequent testing or treatments. Although prime culture is preferably left untreated, either the prime culture or a subculture thereof can be propagated as a reference culture.
  • the reference culture is a culture which is treated with therapies reflective of a patient's actual treatment regimen. For instance, if a patient is treated with a chemotherapeutic agent, the reference culture is treated with the same agent in the same concentration.
  • the reference culture can be monitored genotypically and/or phenotypically to reflect actual progress of the proliferative disease or condition in the patient.
  • Treatment of the reference culture need not be limited to anti-cancer therapies, but can reflect all of a patient's treatments.
  • thrombolytic or anti- thrombogenic treatments can be applied to the reference culture to reflect a patient's treatment.
  • Subcultures of either the prime culture or the reference culture can be used for further analysis, such as the genetic analysis techniques of the present invention.
  • the reference culture is indicative of the current state in a patient of a proliferative disease or condition, subcultures of the reference culture are analyzed. At various points in the passage of the control culture and the reference culture, aliquots of cells from those cultures can be stored cryogenically or otherwise.
  • abnormal proliferating cells prepared according to the culture methods of the present invention are then genetically analyzed for markers specific to the proliferative disease-state of the cells.
  • the genetic data obtained thereby is used to simultaneously build and expand tandem genomic/proteomic cancer databases while coordinating present and future genomic/proteomic individual patient assays, thus providing a two-way feedback system.
  • the cells that are analyzed typically are from subcultures of the prime or reference cultures.
  • nucleic acid is isolated from the cells and is analyzed to identify markers that are characteristic of abnormal proliferating cells.
  • the isolated nucleic acid is DNA or RNA.
  • the nucleic acid preferably is analyzed in a microarray for aberrant expression of one or more genes.
  • the microarray contains nucleic acids that are characteristic of known proliferative disease states, as well as nucleic acids, that are not corrected with known proliferative disease states so that previously unknown relationships between gene expression and a proliferative disease or condition may be identified.
  • marker it is meant any genotypic or phenotypic characteristic of a cell or cell population that, alone or in combination with other marker(s), can be used to identify the particular cell type. Markers can be, without limitation, genotypic, such as an insertion, deletion or substitution, or phenotypic, such as the presence of high levels of a receptor or a secreted peptide.
  • nucleic acid purification methods may be found in any one of a number of molecular biology laboratory texts, with purification products or systems also being commercially available from a variety of companies including Stratagene, Bio-Rad Laboratories and Amersham Pharmacia Biotech.
  • Methods for analysis of the nucleic acid derived from the cells also vary broadly.
  • proliferation markers such as the aberrant expression of one or more genes such as, without limitation, the epidermal growth factor receptor (EGFR) cyclin Dl, pl ⁇ cyclin-kinase inhibitor, retinoblastoma (Rb), Tumor-derived Growth Factor B (TGFB) receptor/smad, MDM2 or p53 genes
  • EGFR epidermal growth factor receptor
  • Rb retinoblastoma
  • TGFB Tumor-derived Growth Factor B
  • Microarrays of either known DNAs or unknown DNAs are now commercially available from a number of commercial sources, such as Affymetrix, Incyte Pharmaceuticals, Stratagene, Nanogen and Rosetta Inpharmatics.
  • ESTs expressed sequence tags
  • the National Human Genome Research Institute (NHGRI) also has begun a collaborative research effort entitled "The Microarray Project,” which includes such efforts as the development of microarrays, robotic microarrayers and automated readers.
  • DNA microarrays can include hundreds to many thousands of unique DNA samples covalently bound to a glass slide in a very small area. By hybridizing labeled RNA or mRNA to the array, the altered expression of one or more genes may be identified.
  • total cellular RNA or mRNA is isolated and labeled.
  • Messenger RNA is labeled by synthesizing an oligo-dT-primed first DNA strand using reverse transcriptase and labeled deoxynucleotides su ⁇ h as, without limitation, Cy5-dUTP commercially available from Amersham Pharmacia Biotech. Radiolabeled nucleotides also can be used to prepare radioactive DNA probes.
  • the labeled DNA complementary to the mRNA, is hybridized to the microarray under sufficiently stringent conditions to ensure specificity of hybridization of the labeled DNA to the array DNA.
  • the labeled array is then visualized. Visualization of the array may be conducted in a variety of ways.
  • the intensity of fluorescence for each discreet DNA of the microarray can be measured by an automated process using a confocal microscope or otherwise.
  • the intensity of the fluorescence for each DNA sample in the microarray typically is directly proportional to the quantity of the corresponding species of mRNA in the cells from which the mRNA is isolated. It is possible to label cDNA from two cell types (i.e., normal and diseased proliferating cells) and hybridize equal amounts of both probes to a microarray to identify differences in RNA expression for both normal and diseased proliferating cells.
  • DNA microarrays are possibly the more powerful tools to utilize in combination with the cell culturing method of the present invention due to the increased sensitivity of mRNA quantification protocols when a substantially pure population of proliferating cells are used. For their ease of use and their ability to generate large amounts of data, microarrays are preferred, when practicable. However, certain qualitative assays may be preferred to identify certain markers.
  • RNA or DNA species may be identified by PCR procedures.
  • Known genetic polymo ⁇ hisms or translocations or insertions i.e., retroviral insertions or the insertion of mobile elements
  • the genetic polymo ⁇ hisms may be identified by conducting a PCR reaction using a cDNA template.
  • Aberrant splicing of RNA precursors also may be identified by conducting a PCR reaction using a cDNA template.
  • Small or single nucleotide substitutions may be identified by the direct sequencing of the primary sequence of a given gene by the use of gene-specific oligonucleotides as sequencing primers. Single nucleotide mutations also may be identified through the use of allelic discrimination molecular beacon probes. While the above-mentioned assays are useful in the analysis of nucleic acids derived from cells produced by the culture methods of the present invention, numerous additional methods are broadly known in the general field of molecular biology and molecular diagnostics that may be used in place of the above-referenced methods.
  • An important aspect of the present invention is to provide a system for conducting gene therapy protocols on various malignancies. For instance, chemotherapeutic treatments have been shown to be enhanced by transferring the He ⁇ es Simplex Virus-Thymidine Kinase (HSV-TK) gene into cancer cells in order to create a suicide gene. Cancer cells carrying this mutated gene would be susceptible to the antiviral drug, ganciclovir (GCV).
  • GCV ganciclovir
  • the He ⁇ es Simplex Virus (HSV) produces a Thymidine Kinase that can convert GCV to ganciclovir-monophosphate (GCV-MP), a metabolite that is toxic to cells.
  • Vectors can be produced that contain HSVl-TK from the human stereotype 1 virus as a suicide gene.
  • HSVl-TK sensitizes transfected cells to GCV and also potentiates a strong bystander effect.
  • the response of various malignancies to this gene therapy chemotherapy-sensitization protocol can be ascertained to provide important prognostic information.
  • An important further aspect of the present invention is to provide a system for screening specific tissue samples from individual patients for expressed cellular markers, secreted factors or antigens including tumor antigens characteristic of the tissue sample.
  • a tissue sample from a patient is harvested and grown in a monolayer culture as described above. Culture medium in which the cultures or subcultures thereof is assayed for the presence or absence of certain factors, such as secreted tumor antigens such as, without limitation, PAl-1, u-PA, cancer associated serum antigen (CAS ) or carcinoembryonic antigen (CEA).
  • secreted tumor antigens such as, without limitation, PAl-1, u-PA, cancer associated serum antigen (CAS ) or carcinoembryonic antigen (CEA).
  • RIA radioimmunoassay
  • ELISA enzyme-linked immunosorbent assay
  • the cell cultures grown in this manner may also be assayed histochemically and/or immunohistochemically for identification or quantification of cellular or membrane-bound markers.
  • markers include, without limitation, CEA, tissue polypeptide specific antigen TPS, EGFR, TGFB receptor and mucin antigens, such as CA 15-3, CA 549, CA 27.29 and MCA.
  • the cultured cells may be further identified aiding the physician in treatment strategies and as a prognosis indicator. Furthermore, by combining the use of the culture technique with assaying for markers as described herein, a treatment strategy for a disease state may be optimized and treatment progression may be monitored.
  • tissue culture medium One important aspect of analyzing tissue culture medium is that complications of a proliferative disease state can be predicted. For instance, one common complication is thrombogenesis.
  • a propensity towards blood clot formation can be detected in tissue culture medium by identifying thrombogenic or procoagulant factors such as, without limitation, cancer cell-derived coagulating activity -1 (CCA-1), the Lewis Y antigen (Ley), HLA-DR and other tumor procoagulants, such as cancer procoagulant (CP) and tissue factor (TF).
  • CCA-1 cancer cell-derived coagulating activity -1
  • Ley Lewis Y antigen
  • HLA-DR tumor procoagulants
  • CP cancer procoagulant
  • TF tissue factor
  • Cells and/or tissue culture media from any of the prime culture, the reference culture or subcultures thereof can be analyzed for tumor aggressiveness and invasiveness markers. Presence of these markers, or absence thereof, is highly relevant to a patient's prognosis. Furthermore, the effect of a given therapy on any of these markers can be analyzed. For instance, a tumor may produce angiogenic factors such as, without limitation, vascular endothelial growth factor (VEGF), which would lead a doctor to give a patient a less favorable prognosis.
  • VEGF vascular endothelial growth factor
  • Other markers can include, without limitation, factors which allow cancer cells to affix to organs other than those from which the cancer cells derive, for instance, beta-3 integrin, which participates in the ability of melanoma cells to adhere to blood vessel walls.
  • the effectiveness of therapies can be assessed if the presence of the angiogenic marker is analyzed in segregated sites according to the method of the present invention.
  • a physician can suppress a malignancy by preventing expression of factors or markers which cause the malignancy's aggressiveness or invasiveness.
  • One application of the present invention is the screening of chemotherapeutic agents and other anti-neoplastic therapies in tissue culture preparations of malignant cells from the patients from whom malignant samples are biopsied.
  • Related anti-cancer therapies which also can be screened using the inventive system include radiation therapy and agents which enhance the cytotoxicity of radiation, as well as immunotherapeutic anti-cancer agents. Screening processes for treatments or therapeutic agents for non-malignant syndromes are also embraced within this invention and include, without limitation, agents which combat hyper-proliferative syndromes, such as psoriasis or wound healing agents.
  • present efficacy assay limited only to the screening of active agents which speed up (healing) or slow down (anti-cancer, anti-hyper- proliferative) cell growth because agents intended to enhance or to subdue intracellular biochemical functions may be tested in the present tissue culture system, also.
  • the formation or blocking of enzymes, neurotransmitters and other biochemicals may be screened with the present assay methods prior to treatment of the patient.
  • a tumor biopsy of >100 mg of non-necrotic, non-contaminated tissue sample is harvested from the patient by any suitable biopsy or surgical procedure known in the art and typically is placed in a shipping container for transfer to a laboratory in which the culturing of the cells according to the present invention is performed.
  • Biopsy sample preparation generally proceeds as follows under a Laminar Flow Hood, which should be turned on at least 20 minutes before use. Reagent grade ethanol is used to wipe down the surface of the hood prior to beginning the sample preparation. The tissue sample is then removed under sterile conditions from the shipping container and is minced with sterile scissors. If the specimen arrives already minced, the individual tumor pieces typically are divided into four groups.
  • each undivided tissue sample quarter is then placed in 3 ml sterile growth medium (Standard F-10 medium containing 17% calf serum and a standard amount of penicillin and streptomycin) and systematically minced by using two sterile scalpels in a scissor-like motion or a mechanically equivalent manual or automated device having opposing incisor blades.
  • This cross-cutting motion is important because the technique creates smooth cut edges on the resulting tumor multicellular particulates.
  • the tumor particulates each measure 1 mm 3 .
  • one-half of the particulates are preserved in a cryoprotectant such as, without limitation, DMSO, glycerol or mannitol.
  • a cryoprotectant such as, without limitation, DMSO, glycerol or mannitol.
  • the preserved particulates are aliquotted into small test tubes labeled with the patient's code, the date of explantation and any other distinguishing data, and then frozen in Dewar bottles containing liquid nitrogen at -40°C.
  • the other half of the particulates are plated in culture flasks using sterile Pasteur pipettes (9 explants per T-25 or 20 particulates per T-75 flask) and each flask is labeled as described above.
  • the explants should be evenly distributed across the bottom surface of the flask with initial inverted incubation in a 37°C incubator for 5-10 minutes, followed by addition of about 5-10 ml sterile growth medium and further incubation in the normal, non-inverted position. Flasks are placed in a 35°C, non-CO 2 incubator. Flasks should be checked daily for growth and contamination. Over a period of a few weeks, with weekly removal and replacement of 5 ml of growth medium, the explants will foster growth of cells into a monolayer.
  • the use of the above procedure to form a cell monolayer culture maximizes the growth of abnormal proliferating cells from the tissue sample and, thus, optimizes ensuing tissue culture assays.
  • Enhanced growth of actual abnormal proliferating cells is only one aspect of the present invention; however, another important feature is the growth rate monitoring system used to oversee growth of the monolayer once formed. Once a primary culture and its derived secondary monolayer tissue culture has been initiated, the growth of the cells is monitored to ascertain the time to initiate the chemotherapy assay and to determine the growth rate of the cultured cells.
  • Monitoring of the growth of cells is conducted by counting the cells in the monolayer on a periodic basis, without killing or staining the cells and without removing any cells from the culture flask.
  • the counting may be done visually or by automated methods, either with or without the use of estimating techniques known in the art (counting in a representative area of a grid multiplied by number of grid areas, for example).
  • Data from periodic counting is then used to determine growth rates which may or may not be considered parallel to growth rates of the same cells in vivo in the patient. If growth rate cycles can be documented, for example, then dosing of certain active agents can be customized for the patient. The same growth rate can be used to evaluate radiation treatment periodicity, as well. It should be noted that with the growth rate determinations conducted while the monolayers grow in their flasks, the present method requires no hemocytometry, flow cytometry or use of microscope slides and staining, with all their concomitant labor and cost.
  • Protocols for monolayer growth rate generally use a phase-contrast inverted microscope to examine culture flasks incubated in a 37°C (5% CO 2 ) incubator.
  • ten fields areas on a grid inherent to the flask
  • the ten fields are examined using the l Ox objective, with the proviso that the ten fields should be non-contiguous, or significantly removed from one another, so that the ten fields are a representative sampling of the whole flask.
  • Percentage cell occupancy for each field examined is noted, and averaging of these percentages then provides an estimate of overall percent confluency in the cell culture.
  • an average cell count for the total patient sample should be calculated.
  • the calculated average percent confluency should be entered into a process log to enable compilation of data-and plotting of growth curves—over time.
  • Monolayer cultures may be photographed to document cell mo ⁇ hology and culture growth patterns.
  • the applicable formula is:
  • Percent confluency estimate of the area occupied by cells total area in an observed field.
  • percent confluency is 30/100, or 30%.
  • Dynamic assays, genomic/proteomic database building, and micro version genomic/proteomic patient assays, as well as active agent and/or radiation therapy screening using the cultured cells proceeds with subcultures of the prime culture or, preferably, of the reference culture.
  • Cultured cells used for dynamic assay analyses are placed in incubation flasks. Therapy screening can be carried out in incubation flasks but generally proceeds using plates, such as microtiter plates.
  • a chemotherapy/radiotherapy assay it is desirable to grow a control culture of a patient's cells in a culture parallel to the reference or prime culture.
  • the control culture can be grown from skin cells of the patient, as an easy source of non-malignant cells, from the same organ from which the malignant cells are derived, or from other sources, so long as the cells are typical of non-malignant cells of the patient.
  • the performance of the chemosensitivity/radiosensitivity assay used for screening pu ⁇ oses depends on the ability to deliver a reproducible cell number to each row in a plate and/or a series of plates, as well as the ability to achieve an even distribution of cells throughout a given well.
  • the following procedure assures that cells are reproducibly transferred from flask to microtiter plates, and cells are evenly distributed across the surface of each well.
  • the first step in preparing the microtiter plates is, of course, preparing and monitoring the monolayer as described above.
  • the following protocol is exemplary and susceptible of variation as will be apparent to one skilled in the art. Cells are removed from the culture flask and a cell pellet is prepared by centrifugation.
  • the cell pellet derived from the monolayer is then suspended in 5 ml of the growth medium and mixed in a conical tube with a vortex for 6-10 seconds. The tube is then rocked back and forth ten times. A 36 ⁇ l droplet from the center of the conical tube is pipetted onto one well of a 96-well plate. A fresh pipette is then used to pipette a 36 ⁇ l aliquot of trypan blue solution, which is added to the same well, and the two droplets are mixed with repeated pipette aspiration. The resulting admixture is then divided between two hemocytometer chambers for examination using a standard light microscope. Cells are counted in two out of four hemocytometer quadrants under lOx magnification.
  • microtiter plates After the microtiter plates have been prepared, exposure of the cells therein to active agent and/or radiation is conducted according to the following exemplary protocol. During this portion of the inventive assay, the appropriate amount of specific active agent is transferred into the microtiter plates prepared as described above.
  • a general protocol which may be adapted, follows. Each microtiter plate is unwrapped from its wet cotton gauze sponge and microscopically examined for cell adhesion. Control solution is dispensed into delineated rows of wells within the grid in the microtiter plate, and appropriate aliquots of active agent to be tested are added to the remaining wells in the remaining rows. Ordinarily, sequentially increasing concentrations of the active agent or higher doses of radiation being tested are administered into progressively higher numbered rows in the plate.
  • the plates are then rewrapped in their gauze and incubated in an incubator box at 37°C under 5% CO 2 . After a predefined exposure time, the plates are unwrapped, blotted with sterile gauze to remove the agent, washed with Hank's Balance Salt Solution, flooded with growth medium, and replaced in the incubator in an incubator box for a predefined time period after which the plates may be fixed and stained for evaluation.
  • Fixing and staining may be conducted according to a number of suitable procedures. The following is representative. After removal of the plates from the incubator box, culture medium is poured off and the plates are flooded with Hank's Balance Salt Solution. After repeated flooding (with agitation each time) the plates are then flooded with reagent grade ethanol for 2-5 minutes. The ethanol is then poured off.
  • Staining is accomplished with approximately 5 ml of Giemsa stain per plate, although volume is not critical and flooding is the goal. Giemsa stain should be left in place 5 min. ⁇ 30 sec. as timing influences staining intensity.
  • the Giemsa stain is then poured off and the plates are dipped three times in cold tap water in a beaker. The plates are then inverted, shaken vigorously, and air dried overnight (with plate lids off) on a rack on a laboratory bench. Cells per well are then counted manually or by automated and/or computerized means to derive data regarding chemosensitivity of cells at various concentrations of exposure.
  • One particularly useful computer operating environment for counting cells is the commercially available OPTTMATE compiler, which is designed to permit an optical counting function well suited to computerized cell counting procedures and subsequent calculations.
  • the above procedures do not change appreciably when cell growth promoters are assayed rather than cell arresting agents, such as chemotherapeutic or radiotherapeutic agents.
  • the present assay allows cell death or cell growth to be monitored with equal ease.
  • optimization of use of the present system will involve the comparative testing of a variety of candidate active agents for selection of the best candidate for patient treatment based upon the in vitro results.
  • One particularly advantageous embodiment of the above-described invention comprises a two-stage assay for cytotoxicity followed by evaluation of longer-term inhibitory effect. Chemotherapeutic agents may thus be evaluated separately for both their direct chemotherapeutic effect as well as for their longer duration efficacy.
  • a control culture in parallel with growth of the prime or reference culture, can be grown.
  • the control culture is a culture of normal cells taken from the same patient from whom the prime culture is collected.
  • the control culture can derive from an epithelial cell sample or can be collected from the same organ as the prime culture so long as the control culture contains no abnormal proliferating cells. More than one control culture can be maintained. For instance, cultures of both normal skin cells and normal cells of an organ from which the malignancy is derived can be maintained. The value of maintaining a control culture is many fold.
  • the control culture serves as a negative control (or positive control depending upon the marker to be analyzed) in the various analyses to be carried out on the prime culture, the reference culture or subcultures thereof.
  • a second value of the control culture is an indicator of theratoxicity, the toxicity or undesirable effects of a given therapy upon normal cells.
  • concomitant analysis of the same agents on segregated sites of the control culture would yield an indication of cytotoxicity of the agent with regard to malignant cells versus the theratoxicity of the agent to control cells.
  • a therapeutic index can be calculated based on the ratio of cytotoxicity to malignant cells to theratoxicity. Cytotoxicity and theratoxicity can be quantified as a percentage or fraction of cells killed by a given therapy or as a percentage or fraction of cells surviving a given therapy.
  • a therapeutic index is a ratio of these percentages or fractions and is reflective of the desirability of a given treatment in a patient.
  • An optimal treatment would be maximally cytotoxic (or even cytostatic) to the malignant cells and minimally toxic to a patient's normal cells.
  • indices may be generated depending upon the desired effect of a therapy. For instance, if a desired therapy is designed to up-regulate a malignancy- specific antigen to promote destruction of the malignancy by a patient's immune system, an index could be generated to discern a treatment which reflects maximal up-regulation of the antigen in the malignant cells and minimal or negative up-regulation in a patient's normal cells. A similar index can be calculated based upon down-regulation of a desired marker (i.e., an angiogenic factor) which can be assayed as either a secreted or a cellular marker and reflects maximal down-regulation of the marker with minimal theratoxicity or other undesirable effects on the control culture.
  • a desired marker i.e., an angiogenic factor
  • the diseased cells express a cellular marker that is indicative of a certain disease state or lack thereof.
  • the cultured diseased cells do not necessarily have to be the cells expressing the factor to be assayed.
  • One question that inevitably arises when considering whether a serum marker is indicative of a particular cancer cell is: which cells produce the marker, the cell or the tissue in which the cancer cells grow? By co-culturing the cancerous tissue within a multicellular particulate of its originating tissue, the cells (both the diseased cells or the surrounding cells) are better able to retain their production of characteristic markers.
  • One important focus of the present invention thus includes the simplicity of the present system-cohesive multicellular particulates of the patient tissue to be tested are used to form cell monolayers; growth of those monolayers is monitored for accurate prediction of correlating growth of the same cells in vivo; differing concentrations of a number of active agents may be tested for the pu ⁇ ose of determining not only the most appropriate agent but the most appropriate concentration of that agent for actual patient exposure (according to the calculated cell growth rates), and the cultured cells can be tested for the presence of abnormal markers, such as genetic markers.
  • the present system allows in vitro tests to be conducted in suspensions of tissue culture monolayers grown in nutrient medium, under fast conditions (a matter of weeks), rather than with single cell progeny produced by dilution cloning over long periods of time.
  • the present invention is a two- stage assay for both cytotoxicity and the longer-term growth inhibitory. It is additionally possible to increase the value of the assay with the use of staining compositions and protocols designed to characterize the malignant cells thus grown.
  • the tissue preparation and cell culturing technique itself offers a first assurance that the cells grown out of the tumor are really the malignant tumor cells and not fibroblasts or other non-malignant cells of no diagnostic value.
  • the present staining compositions and protocols offer a second, independent assurance that the cells subject to diagnostic or prognostic assay are, in fact, malignant cells in culture.
  • One important characterization has to do with the nature of the malignant cells as epithelial, which is in turn an indicator of the carcinoma type of malignancy.
  • Other characterizations of malignant cells are intended to fall within the scope of the present invention as well, although the characterization of the cells as epithelial or not is of primary importance.
  • the technique is practiced as follows.
  • the same cell culturing and well distribution process is used as in the cytotoxicity assay described above, but rather than exposing the cells to chemotherapeutic or other agents, the cells are instead fixed and stained.
  • the stain or stain cocktail described below the epithelial cells are identified by their intermediate filaments and/or specific membrane antigens by means of a monoclonal antibody immunoperoxidase technique.
  • the fixative used can be any fixative which does not alter the cellular molecular markers of interest.
  • the fixed stained cells are then counted. If the specimen is positive for epithelial cells, the process is complete. If the specimen is negative for epithelial cells, an independent fixing and staining process is subsequently completed, with fresh cells from identical wells, using Vimentin as a stain to confirm the non-epithelial nature of the cells.
  • tissue culture technique is designed to grow out the cells of the tumor of origin and, in fact, consistently does so.
  • the fact that the cells of the tumor of origin did, in fact, grow out, and not fibroblasts or other cells must be confirmed with independent proof before the cells can be used with complete assurance in the appropriate patient assay(s).
  • the present technology provides a means to obtain this confirmation which, in turn, furthers the interests of good laboratory and medical practice.
  • the staining compounds or compositions of interest for use in the present technology are those which bind with cellular molecular markers unique either to epithelial or to non-epithelial cells.
  • a further aspect of the invention therefore, inheres in the following two aspects: the improvement of the cytotoxicity assay by adding the epithelial staining protocol with any known epithelial stain; and the further improvement wherein specially designed stain cocktails maximize the likelihood that the presence of any known intermediate filament or specific membrane antigen characteristic of epithelial cells will be identified, if present.
  • carcinomas are positive for any one of the intermediate filaments or specific membrane antigens characteristic of epithelial cells. Virtually all, if not all, carcinomas are positive for one of a number of such intermediate filaments or specific membrane antigens.
  • "epithelial membrane antigen” (EMA) glycoproteins are known in the art and can be bound with various anti-epithelial membrane antigen antibodies including monoclonal antibodies.
  • Cytokeratin is another important epithelial cell marker and binding reagents including monoclonal antibodies are available which are specific to cytokeratin. While antisera can be raised in vivo against markers such as EMA glycoproteins and cytokeratin, as a practical matter, commercially available polyclonal or monoclonal antibodies are used in the following protocols, with monoclonal antibodies being preferred.
  • the "labeled streptavidin procedure” In this procedure, after the specimen is exposed to antibodies specific to the target antigen, a secondary “link” antibody is added.
  • the secondary biotinylated “link” antibody consists of anti-mouse and anti-rabbit antibodies which bind universally to most primary monoclonal or polyclonal antibodies.
  • the "link” will also connect to the tertiary reagent (peroxidase-labeled streptavidin) through chemical bonding between the biotin on the secondary reagent and the streptavidin on the streptavidin/peroxidase conjugate.
  • Staining is completed by incubating the specimen and primary, secondary and tertiary agents in the presence of a chromogen, so that the peroxidase and the chromogen form a visible precipitate.
  • a fluorescein-based detection system can be used to visualize the primary antibody, or a third alternative known in the art as the digoxigenin-conjugated detection system may be used.
  • EMA glycoproteins Of the various epithelial markers, three have received the most widespread attention in the literature: EMA glycoproteins, cytokeratin, and carcinoembryonic antigen.
  • the first two are the most important because literally any epithelial cell will have at least either one EMA glycoprotein on the surface thereof or a cytokeratin intermediate filament present. Therefore, the present invention resides not only in binding and staining for an epithelial marker on the surfaces of the specimen cells, but in simultaneously assaying for either or both of EMA glycoprotein(s) and cytokeratin.
  • the cocktails of the present invention therefore, contain binding reagents for both EMA glycoproteins and cytokeratin and, importantly, are selected to include the most generally applicable binding reagents in combination so that the cocktail has the broadest binding scope possible.
  • the cocktails identified in Examples 1 and 2 represent a combination of two general binding reagents (containing a total of three monoclonal antibodies) for cytokeratin, admixed with a general binding reagent for EMA glycoprotein.
  • the dual benefit of this admixture of general binding agents is that the incidence of false negatives for epithelial cells is minimized and the visible staining reactions are generally stronger when the combined binding reagents are used in lieu of a single binding reagent.
  • Examples are the preferred reagents for use in the context of the invention, the invention is intended to encompass epithelial-specific binding and staining reagents generally. These include, without limitation, Boehringer-Mannheim AEl anti-cytokeratin antibody; Boehringer-Mannheim AE3 anti-cytokeratin antibody; Boehringer-Mannheim AE1/AE3 anti-cytokeratin antibody (AEl and AE3 in admixture); Becton-Dickinson CAM 5.2 antibody; DAKO EMA antibody; Biomeda's Anti-Cytokeratin Cocktail CK22; Biomeda's Anti-Cytokeratin Cocktail CK23; Biomeda's Anti-Pan-Cytokeratin CK56; Biomeda's polyclonal goat or rabbit anti-cytokeratin antisera; ScyTek Laboratories anti-EMA antigen antibody clone E29; and many others.
  • Boehringer-Mannheim AEl anti-cytokeratin antibody
  • binding agents and cocktails may be used in combination with any known visualization system, such as the streptavidin-, fluorescein- and digoxigenin-conjugated systems identified above.
  • Vimentin antibody is used as a binding alternative either in conjunction with binding and staining of the test cells or subsequently thereto.
  • Vimentin can be considered a binding reagent which is specific to non-epithelial cells.
  • immunological markers may be monitored in applications requiring up- or down-regulation of such markers (i.e., major histocompatability complex molecules).
  • This aspect of the present invention can be especially useful in transplantation applications where, for instance, through chemical or biological means, rejection of transplanted cells is sought to be avoided by down- regulation of the various transplantation antigens present on the cells to be transplanted.
  • the present invention would be especially useful in monitoring such immunoregulation.
  • cell mo ⁇ hology can be assayed by culturing cells of, i.e., the prime culture or the reference culture; removing the cells from the surface upon which they grow; centrifuging the cells into a loose pellet; and growing the cell pellet over a defined time period. By growing cells in this manner, it is possible to view the cohesive mo ⁇ hology of cells in a cluster resembling a tumor.
  • Enough cells were then removed from the monolayers grown in the flasks for centrifugation into standard size cell pellets for each of the 16 flasks.
  • Each cell pellet was then suspended in 5 ml of the above-described medium and was mixed in a conical tube with a vortex for 6-10 seconds, followed by manual rocking back and forth ten times.
  • a 36 ml droplet from the center of each tube was then pipetted into one well of a 96-well microtiter plate together with an equal amount of trypan blue, plus stirring. The resulting admixture was then divided between two hemocytometer quadrants for examination using a standard light microscope.
  • the cells were irradiated using a Siemens Stabilipan X-ray machine at 250 kVp, 15mA with a dose rate of 75 rad/minute.
  • a Siemens Stabilipan X-ray machine at 250 kVp, 15mA with a dose rate of 75 rad/minute.
  • cell number per well was monitored as a function of time through five days post-irradiation.
  • the resulting admixture was then divided between two hemocytometer quadrants for examination using a standard light microscope. Cells were counted in two out of four hemocytometer quadrants under lOx magnification— only those cells which had not taken up the trypan blue dye were counted. This process was repeated for the second counting chamber. An average cell count per chamber was calculated and by means known in the art, the optimum concentration of cells in the medium was determined.
  • Example 3 Gene Therapy/Antisense Oligonucleotides
  • a 50 mg sample from a residual human mesothelioma was minced in medium with sterile scissors to a particle size of roughly 1 mm and with a particle size distribution between about .25 and about 1.5 mm 3 .
  • the medium was Standard F-10 medium containing 17% calf serum and a standard amount of penicillin and streptomycin.
  • the 50 mg sample was minced and was divided into four groups of particulates and each of four groups was charged to a separate labeled culture flask containing the above-described medium. Visual confirmation was made that the particulates were evenly distributed along the bottom of each flask and the flasks were placed in a 35°C, non-CO 2 incubator. Flasks were checked daily for growth and contamination. Over a period of a few weeks, with weekly removal and replacement of 5 ml of growth medium, the particulates grew into monolayers.
  • Enough cells were then removed from the monolayers grown in the flasks for centrifugation into standard size cell pellets for each of the four flasks.
  • Each cell pellet was then suspended in 5 ml of the above-described medium and was mixed in a conical tube with a vortex for 6-10 seconds, followed by manual rocking back and forth ten times.
  • a 36 ml droplet from the center of each tube was then pipetted into one well of a 96-well microtiter plate together with an equal amount of trypan blue, plus stirring. The resulting admixture was then divided between two hemocytometer quadrants for examination using a standard light microscope.
  • the antisense oligonucleotide for the urokinase-type plasminogen activator receptor was delivered to wells in the microtiter plate. Proteolysis of plasminogen to plasmin by urokinase-type plasminogen activator has been implicated in the processes of tumor cell proliferation and invasion.
  • the concentrations of the uPAR antisense oligonucleotide were 1, 10 and 100 micromolar.
  • uPAR sense and missense oligonucleotides at the concentrations of 1, 10 and 100 micromolar served as controls.
  • the tumor cells were exposed to the oligonucleotides for 24 hours and then the agents were removed. The cells were allowed to incubate for another 72 hours so that inhibition of cell proliferation could be observed.
  • Antisense oligonucleotides to uPAR suppressed the proliferative activity of the tumor cells in a concentration-dependent manner.
  • a 50 mg sample from a residual human ovarian cancer was minced in medium with sterile scissors to a particle size of roughly 1 mm and with a particle size distribution between about .25 and about 1.5 mm .
  • the medium was Standard F-10 medium containing 17% calf serum and a standard amount of penicillin and streptomycin. After each tissue sample quarter has been minced, one-half of the particulates was preserved in DMSO. The preserved particulates were aliquotted into small test tubes labeled with the patient's code, the date of explantation and any other distinguishing data, and frozen in Dewar bottles containing liquid nitrogen at -40 C C.
  • the other half of the particulates was plated in culture flasks using sterile Pasteur pipettes (9 explants per T-25 or 20 particulates per T-75 flask) and each flask was labeled as described above. Visual confirmation was made that the particulates were evenly distributed along the bottom of each flask and the flasks were placed in a 35°C incubator. Over a period of a few weeks, with weekly removal and replacement of 5 ml of growth medium, the particulates grew into monolayers.
  • Enough cells were then removed from the monolayers grown in the flasks for centrifugation into standard size cell pellets. Each cell pellet was then carefully removed from the centrifuge tube and plated onto a sterile culture flask in Standard F-10 medium containing 17% calf serum and a standard amount of penicillin and streptomycin and placed in a 37°C CO 2 incubator.
  • the control group consisting of one-half of the tumor pellets, received by needle transfer an adenovirus vector carrying the lacZ marker gene and an appropriate dose of GCV.
  • the treatment group received by needle transfer an adenovirus vector carrying the HSV-TK gene and an appropriate dose of
  • HSV-TK/GCV gene therapy produced moderate and diffuse degeneration of the cancer cells in the treatment group when compared to the control group.
  • the resulting admixture was then divided between two hemocytometer quadrants for examination using a standard light microscope. Cells were counted in two out of four hemocytometer quadrants under lOx magnification— only those cells which had not taken up the trypan blue dye were counted. This process was repeated for the second counting chamber. An average cell count per chamber was calculated and, by means known in the art, the optimum concentration of cells in the medium was determined.
  • the chemotherapeutic agent Taxol was applied to the wells in the microtiter plates.
  • the first three treatment rows in the plates (rows 2, 3, and 4) were designed to have escalating Taxol doses (1.0, 5.0, and 25 ⁇ M) with a fixed carboplatin dose (200 ⁇ M).
  • the last three treatment rows in the plates (rows 6, 7, and 9) were designed to have a fixed Taxol dose (5 ⁇ M) with an escalating carboplatin dose (50, 200, and 1000 ⁇ M).
  • Rows 5 and 9 served as a control.
  • the Taxol exposure time was two hours. Twenty-four hours later, the cells in the wells were exposed to carboplatin for two hours. The tumor cells in the wells were then incubated for another 48 hours.
  • the medium was Standard F-10 medium containing 17% calf serum and a standard amount of penicillin and streptomycin. Each 50 mg sample was minced and divided into four groups of particulates and each of 16 groups was charged to a separate labeled culture flask containing the above-described medium. Visual confirmation was made that the particulates were evenly distributed along the bottom of each flask and the flasks were placed in a 35°C, non-CO 2 incubator. Flasks were checked daily for growth and contamination. Over a period of a few weeks, with weekly removal and replacement of 5 ml of growth medium, the particulates grew into monolayers.
  • Enough cells were then removed from the monolayers grown in the flasks for centrifugation into standard size cell pellets for each of the 16 flasks.
  • Each cell pellet was then suspended in 5 ml of the above-described medium and mixed in a conical tube with a vortex for 6-10 seconds, followed by manual rocking back and forth ten times.
  • a 36 ml droplet from the center of each tube was then pipetted into one well of a 96-well microtiter plate together with an equal amount of trypan blue, plus stirring. The resulting admixture was then divided between two hemocytometer quadrants for examination using a standard light microscope.
  • Tamoxifen solutions in the concentration range of 10 nM to 20 ⁇ M.
  • Six doses of Tamoxifen were used for cells from each of the four breast tumor specimens.
  • An ethanol solution at a concentration equivalent to that at the highest Tamoxifen concentration served as a control.
  • the tumor cells were exposed to Tamoxifen for 24 hours and then the agent was removed.
  • the cells were allowed to incubate for another 72 hours so that inhibition of cell proliferation could be observed.
  • the resulting admixture was then divided between two hemocytometer quadrants for examination using a standard light microscope. Cells were counted in two out of four hemocytometer quadrants under lOx magnification— only those cells which had not taken up the trypan blue dye were counted. This process was repeated for the second counting chamber. An average cell count per chamber was calculated and by means known in the art, the optimum concentration of cells in the medium was determined. Accommodating the above calculations, additional cell aliquots from the
  • 16 monolayers were separately suspended in growth medium via vortex and rocking and were loaded into a Terasaki dispenser adapted to a 60-well plate. Aliquots of the prepared cell suspension were delivered into the microtiter plates using Terasaki dispenser techniques known in the art. Cells were plated into 60-well microtiter plates at a concentration of 100 cells per well.
  • retinoic acid was delivered to wells in the microtiter plates.
  • a stock solution of retinoic acid was initially prepared by dissolving retinoic acid powder in 1 ml of DMSO and then adding 9 ml of growth medium. This stock solution was then used to make retinoic acid solutions in the concentration range of 0.1 to 1.0 mM.
  • Six doses of retinoic acid were used for cells from each of the four breast tumor specimens.
  • a DMSO solution at a concentration equivalent to that at the highest retinoic acid concentration served as a control.
  • the tumor cells were exposed to retinoic acid for 24 hours and then the agent was removed. The cells were allowed to incubate for another 72 hours so that inhibition of cell proliferation could be observed.
  • the resulting admixture was then divided between two hemocytometer quadrants for examination using a standard light microscope. Cells were counted in two out of four hemocytometer quadrants under lOx magnification— only those cells which had not taken up the trypan blue dye were counted. This process was repeated for the second counting chamber. An average cell count per chamber was calculated and by means known in the art, the optimum concentration of cells in the medium was determined.
  • a second set of plates was designed to have a fixed Taxol dose (5 ⁇ M) with an escalating radiation dose (1 Gy-6 Gy).
  • the cells in the plates were irradiated using a Siemans Stabilipan X- ray machine operating at 250 kVp, 15 mA with a dose rate of 75 rad/min.
  • a tumor biopsy of approximately 100 mg of non-necrotic non- contaminated tissue was harvested from the patient by surgical biopsy and transferred to the laboratory in a standard shipping container.
  • Biopsy sample preparation proceeded as follows: Reagent grade ethanol was used to wipe down the surface of a Laminar Flow Hood. The tumor was then removed under sterile conditions from its shipping container and cut into quarters with a sterile scalpel. Using sterile forceps, each undivided tissue quarter was then placed in 3 ml sterile growth medium (Standard F-10 medium containing 17%o calf serum and a standard amount of penicillin and streptomycin) and was systematically minced by using two sterile scalpels in a scissor-like motion.
  • Standard F-10 medium containing 17%o calf serum and a standard amount of penicillin and streptomycin
  • the tumor particulates each measured about 1 mm 3 . After each tumor quarter was minced, the particulates were placed in culture flasks using sterile Pasteur pipettes (9 explants per T-25 or 20 particulates per T-75 flask). Each flask was then labeled with the patient's code, the date of explantation and any other distinguishing data. The explants were evenly distributed across the bottom surface of the flask, with initial inverted incubation in a 37°C incubator for 5-10 minutes, followed by addition of about 5-10 ml sterile growth medium and further incubation in the normal, non-inverted position. Flasks were placed in a 35°C, non-CO 2 incubator. Flasks were checked daily for growth and contamination. Over a period of a few weeks, with weekly removal and replacement of 5 ml of growth medium, the explants grew out into a monolayer.
  • the growth rate of the cells was determined until the chemosensitivity assay was performed. During this time period, the growth was monitored by observing the percent of confluency of the cells in a flask. These data provide information valuable as a correlation to possible growth of the tumor in the patient, as well as for the inte ⁇ retation of the results of the chemosensitivity assay. Three examples of growth rate data are shown in Figs 1 A-IC. The percent of confluency of the cultured cells is plotted as a function of time after the initial seeding of the tissue specimen.
  • tumor specimens will contain a mixture of cancer and normal cells. Although in many cases tumor cells will readily grow in tissue culture while the normal cells will not, it is important to be able to distinguish the two cell types. Using immunoperoxidase techniques to stain cells for various intermediate filaments, the differences between normal (fibroblast-like) cells and cells from epithelial tumors were characterized. These techniques can also be used to identify other tumor cell characteristics which may have prognostic value.
  • epithelial tumor cell lines all have stained positively for a mixture ("cocktail") of epithelial intermediate filament antibodies (not every line, however, has stained positively for the three antibodies within the mixture [AE1/AE3; Cam 5.2; EMA]).
  • Some of the epithelial tumor cells in culture also stained mildly positive for an antibody against an intermediate filament characteristic of fibroblasts (vimentin). When staining for fibroblast intermediate filament (vimentin) in cell culture, all fibroblast cells were positive. Some focal staining by epithelial tumor cells for vimentin was also present.
  • Vimentin appears to be a method of distinguishing certain characteristics of tumor and normal cells.
  • the tissue culture chemosensitivity assay has been refined to make it more sensitive for the detection of damage produced by a variety of chemotherapeutic agents.
  • the initial alteration was to allow a 24-hour time period between plating of cells in microtiter wells and the exposure to drugs. This time interval permits cells to be in an active state of proliferation where they are more sensitive to cell cycle active agents.
  • the second change was to initiate a long-term assay (growth inhibition assay) over a period of about 72 hours.
  • the short-term assay is conducted 24-72 hours after the therapeutic agent is added.
  • the longer time between drug exposure and assay allows for the detection of cell damage which occurs over a protracted period and requires several cell division cycles before it becomes apparent.
  • "CI" Cytotoxicity Index
  • the data for a short-term assay and a long-term assay performed on two sets of patient cultured cells are presented in Figs. 2A-2F through Figs. 5A-5F.
  • the long- term assay (Figs. 3 A-3F and Figs. 5 A-5F) may both accentuate a positive result obtained from the short-term assay (Figs. 2A-2F and Figs. 4A-4F) and reveal an effect not observed during the short-term assay.
  • the long-term assay is now inco ⁇ orated into the tissue culture chemosensitivity on a routine basis.
  • D. Response to Radiation Therapy The use of the microtiter well assay to analyze the direct effect of radiation therapy on tumor cells in culture has resulted in a rapid evaluation method for the determination of inherent cellular radiation response.
  • two radiation dose- response curves generated from the microtiter well assay are presented in Figs. 6 and 7.
  • the cells from the tumor specimen in Fig. 6 are more resistant than those of the specimen in Fig. 7.
  • the more resistant tumor has been previously irradiated.
  • microtiter well assay is ideally suited for examination of the interaction of chemotherapeutic agents and radiation. Issues such as the differential sensitivity of drug/radiation combinations and the timing of drug/radiation combinations may be directly addressed with this system.
  • An illustration of chemotherapeutic agent enhancement of radiation response is presented in Figs. 8A-8C.
  • Activated lymphocytes are being used as a treatment for some types of cancer. These Activated Natural Killers (ANK) cells have been shown to mediate highly efficient cell killing for some tumor types.
  • the microtiter well assay can be utilized to make a rapid assessment of ANK-induced tumor target cell killing. An illustration of two such interactions is presented in Figs. 9A and 9B.
  • the target cells were from a melanoma and a renal carcinoma, respectively.
  • the target cells were exposed to the ANK cells for four hours and then the assay was performed.
  • the effector target cell ratio varied from 1 :2.5 to 1:20.
  • the data show increasing cell killing as a function of increasing effector target ratio.
  • a number of substances secreted by tumor cells are believed to regulate a variety of processes involved in the progression of malignant disease. Many of these factors are produced by tumor cells growing in tissue culture and are secreted into the growth medium. The measurement of these factors in the medium from cell cultures of tumor specimens may prove to be of predictive value in the assessment of the biological behavior of individual cancers. Preliminary work in this area has been on the detection of plasminogen activator inhibitor in the growth medium of glioblastoma cell lines. Plasminogen activator inhibitor expression has been shown to be increased in patients with malignant brain tumors. Medium from glioblastoma cell lines showed an increase in plasminogen activator inhibitor when compared to the medium alone.
  • Indices can be automatically calculated by a computer which is programmed appropriately. Data can be input into the computer either manually or automatically, into a spreadsheet or database program, or the like.
  • the spreadsheet or database program can be programmed to reduce the data to the indices described above, or to any other relevant form, i.e., graphical or figurative representations of the data.
  • the cells to be assayed are grown on microtiter plates and assayed for their sensitivity to a chemotherapeutic agent according to the above-described protocols.
  • the microtiter plates are read on an optical scanner and data from the scanner is automatically exported to a computer for calculation of a therapeutic index.
  • Other types of scanners may be utilized depending upon the assay. For instance, a scanner for reading RIA data would be provided if the assay is an RIA assay.
  • a tumor biopsy was obtained and cultured according to the culture method of the present invention and total cellular RNA was isolated.
  • PolyA RNA was isolated from the total cellular RNA by passage of the total cellular RNA over an oligo-dT cellulose column.
  • Approximately 1 ⁇ g of polyA RNA was labeled with Cy3-dUTP, commercially available from Amersham Pharmacia Biotech, in a first strand cDNA synthesis reaction using reverse transcriptase.
  • the fluorescently labeled cDNA was hybridized under stringent conditions to a microarray of DNA corresponding to genes expressed in commercially available cancer cells. The intensity of the fluorescence for each DNA of the microarray was measured and stored in a computer database.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • Medical Informatics (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Databases & Information Systems (AREA)
  • Wood Science & Technology (AREA)
  • Bioethics (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un nouveau procédé pour la production de données caractérisant les acides nucléiques dans des cellules de prolifération mettant en oeuvre un protocole en tandem pour la construction et l'expansion simultanées des bases de données de cancers génomique/protéomique tout en assurant la coordination des analyses génomiques/protéomiques présentes et futures de patients individuels par le recueil de prélèvement de tissus comportant des cellules de prolifération; la division mécanique du prélèvement en matières particulaires cellulaires, et la culture et l'analyse des cellules obtenues. On peut analyser des ensembles de données génétiques en combinaison avec des ensembles de données cliniques correspondantes, comportant des données phénotypiques, en vue de constituer des profils susceptibles de permettre l'identification de maladies proliférantes et des pronostics. L'invention concerne également un procédé diagnostique de maladies proliférantes mettant en oeuvre lesdits procédés d'analyse. Enfin, l'invention concerne un dispositif informatique permettant l'analyse de la recherche et la saisie de données génétiques, des données cliniques et/ou les profils correspondants.
PCT/US2001/032540 2000-10-18 2001-10-18 Procede d'analyses genomique/proteomique en tandem de cellules de proliferation WO2002033117A2 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2002224435A AU2002224435A1 (en) 2000-10-18 2001-10-18 Method for tandem genomic/proteomic analyses of proliferating cells
US10/399,563 US20040086888A1 (en) 2001-10-18 2001-10-18 Method for tandem genomic/proteomic analysis of proliferating cells

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US69149200A 2000-10-18 2000-10-18
US09/691,492 2000-10-18
US27328101P 2001-03-02 2001-03-02
US60/273,281 2001-03-02

Publications (2)

Publication Number Publication Date
WO2002033117A2 true WO2002033117A2 (fr) 2002-04-25
WO2002033117A3 WO2002033117A3 (fr) 2002-06-27

Family

ID=26956065

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2001/032540 WO2002033117A2 (fr) 2000-10-18 2001-10-18 Procede d'analyses genomique/proteomique en tandem de cellules de proliferation

Country Status (2)

Country Link
AU (1) AU2002224435A1 (fr)
WO (1) WO2002033117A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887680B2 (en) 1996-07-12 2005-05-03 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US7575868B2 (en) 1996-07-12 2009-08-18 Precision Therapeutics, Inc. Methods for assessing efficacy of chemotherapeutic agents
US7642048B2 (en) 2005-09-01 2010-01-05 Precision Therapeutics Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
US7972769B2 (en) 1996-07-12 2011-07-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789158A (en) * 1992-06-30 1998-08-04 The Wistar Institute Of Anatomy And Biology Developmental embryonic mouse cDNA libraries
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5789158A (en) * 1992-06-30 1998-08-04 The Wistar Institute Of Anatomy And Biology Developmental embryonic mouse cDNA libraries
US6335170B1 (en) * 1999-02-22 2002-01-01 Torben F. Orntoft Gene expression in bladder tumors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
M.E. BURCZYNSKI ET AL.: 'Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells' TOXICOLOGICAL SCIENCES vol. 58, no. 2, December 2000, pages 399 - 415, XP002909258 *
R.E. CILLEY ET AL.: 'Feta lung development: airway pressure enhances the expression of development genes' JOURNAL OF PEDIATRIC SURGERY vol. 35, no. 1, January 2000, pages 113 - 119, XP002909257 *
T. GRESS ET AL.: 'Development of a database on transcribed sequences in tumour cells and identification of changes in transcription patterns related to transformation and other tumour cell properties for the global finger printing analysis of human pancreatic carcinoma cDNA libraries' BIOMED. HEALTH RES. vol. 24, 1998, pages 171 - 181, XP000863083 *
T.L. GOLDSWORTHY ET AL.: 'Concepts, labeling procedures and design of cell proliferation studies relating to carcinogenesis' ENVIRONMENTAL HEALTH PERSPECTIVES vol. 101, no. SUPPL. 5, December 1993, pages 59 - 66, XP002909259 *

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6887680B2 (en) 1996-07-12 2005-05-03 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US6900027B1 (en) 1996-07-12 2005-05-31 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US6933129B1 (en) 1996-07-12 2005-08-23 Precision Therapeutics, Inc. Method for culturing and assaying cells
US7112415B2 (en) 1996-07-12 2006-09-26 Precision Therapeutics, Inc. Method of preparing cell cultures from biological specimens for assaying a response to an agent
US7314731B2 (en) 1996-07-12 2008-01-01 Precision Therapeutics, Inc. Method for selecting therapeutic agents for cancer
US7501260B2 (en) 1996-07-12 2009-03-10 Precision Therapeutics, Inc. Methods for determining efficacy of chemotherapeutic agents for a patient prior to treatment
US7563593B2 (en) 1996-07-12 2009-07-21 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for assaying secreted factors
US7575868B2 (en) 1996-07-12 2009-08-18 Precision Therapeutics, Inc. Methods for assessing efficacy of chemotherapeutic agents
US8183009B2 (en) 1996-07-12 2012-05-22 Precision Therapeutics, Inc. Assaying cellular markers for the evaluation of tumors
US7771963B2 (en) 1996-07-12 2010-08-10 Precision Therapeutics, Inc. Methods for determining efficacy of chemotherapeutic agents
US8058025B2 (en) 1996-07-12 2011-11-15 Precision Therapeutics, Inc. Methods for determining efficacy of chemotherapeutic agents
US7972769B2 (en) 1996-07-12 2011-07-05 Precision Therapeutics, Inc. Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays
US8039213B2 (en) 2002-10-10 2011-10-18 Precision Therapeutics, Inc. Methods for assessing efficacy of chemotherapeutic agents
US7829288B2 (en) 2002-10-10 2010-11-09 Precision Therapeutics, Inc. Methods for assessing efficacy of chemotherapeutic agents
US7642048B2 (en) 2005-09-01 2010-01-05 Precision Therapeutics Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
US8236489B2 (en) 2005-09-01 2012-08-07 Precision Therapeutics, Inc. Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics

Also Published As

Publication number Publication date
AU2002224435A1 (en) 2002-04-29
WO2002033117A3 (fr) 2002-06-27

Similar Documents

Publication Publication Date Title
US6416967B2 (en) Method of using multicellular particulates to analyze malignant or hyperproliferative tissue
US20040086888A1 (en) Method for tandem genomic/proteomic analysis of proliferating cells
US8183009B2 (en) Assaying cellular markers for the evaluation of tumors
US7829288B2 (en) Methods for assessing efficacy of chemotherapeutic agents
US7642048B2 (en) Chemo-sensitivity assays using tumor cells exhibiting persistent phenotypic characteristics
US7332290B2 (en) Dectection of AMACR cancer markers in urine
CN104878086A (zh) 肿瘤的分子谱分析
TW201504438A (zh) 預後分類之方法及套組與以核酸製備治療腺體癌症的醫藥組合物之用途
WO2001033228A9 (fr) Methodes de prognostic et de diagnostic du cancer
CA2397416A1 (fr) Systeme de mise au point d'essais pour des traitements personnalises
WO2002033117A2 (fr) Procede d'analyses genomique/proteomique en tandem de cellules de proliferation
US20080248483A1 (en) Methods of identifying therapeutic compounds in a genetically defined setting
Leelatian et al. High risk glioblastoma cells revealed by machine learning and single cell signaling profiles
EP1179086B1 (fr) Methodes permettant d'identifier des composes therapeutiques dans un contexte genetiquement defini
Liefers et al. Genetic cancer syndromes and large-scale gene expression analysis: applications in surgical oncology
Bonassi et al. Application of biomarkers in human population studies

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ CZ DE DE DK DK DM DZ EC EE EE ES FI FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 10399563

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP